Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1436 participants.

Also called NCT03176186

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,436 participants (planned count) (from the registry)
Sponsor
Invero Pharma, Inc. (from the registry)
Registry
  • NCT NCT03176186
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Denmark (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT03176186. Randomized; single masking; primary purpose treatment. Start 2026-03 (anticipated); primary completion 2029-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest
Acronym
XePOHCAS
Condition
Post-Cardiac Arrest Syndrome
Intervention (Combination product)
Xenon
Lead sponsor
Invero Pharma, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03176186
Content hash
7b5c0ec2fc7ac3686f52fc553787b89fa9ae8275f4e5e25489da324b371b6eb4